Article Text

other Versions

PDF
Original article
End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study
  1. Zainab Ahmadi1,
  2. Nicholas G Wysham2,
  3. Staffan Lundström3,
  4. Christer Janson4,
  5. David C Currow5,
  6. Magnus Ekström1,5
  1. 1Division of Respiratory Medicine & Allergology, Department of Clinical Sciences, Lund University Hospital, Lund, Sweden
  2. 2Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Duke University, Center for Learning Health Care, Duke Clinical Research Institute, Durham, North Carolina, USA
  3. 3Palliative Care Services, Stockholms Sjukhem Foundation, Stockholm, Sweden
  4. 4Department of Medical Sciences, Respiratory Medicine & Allergology, Uppsala University, Uppsala, Sweden
  5. 5Department of Discipline, Palliative and Supportive Services, Flinders University, Adelaide, South Australia, Australia
  1. Correspondence to Dr Zainab Ahmadi, Division of Respiratory Medicine & Allergology, Department of Clinical Sciences, Lund University Hospital, Lund SE-221 00, Sweden; zai.ahmd{at}gmail.com

Abstract

Rationale Advanced fibrosing interstitial lung disease (ILD) is often progressive and associated with a high burden of symptoms and poor prognosis. Little is known about the symptom prevalence and access to palliative care services at end of life (EOL).

Objectives Compare prevalence of symptoms and palliative treatments between patients dying with oxygen-dependent ILD and patients dying of lung cancer.

Methods Nationwide registry-based cohort study of patients with oxygen-dependent ILD and patients with lung cancer who died between 1 January 2011 and 14 October 2013. Prevalence of symptoms and treatments during the last seven days of life were compared using data in Swedish Registry of Palliative Care.

Measurements and main results 285 patients with ILD and 10 822 with lung cancer were included. In ILD, death was more likely to be ‘unexpected’ (15% vs 4%), less likely to occur in a palliative care setting (17% vs 40%) and EOL discussions with the patients (41% vs 59%) were less common than in lung cancer. Patients with ILD suffered more from breathlessness (75% vs 42%) while patients with lung cancer had more pain (51% vs 73%) (p<0.005 for all comparisons). Patients with ILD had more unrelieved breathlessness, pain and anxiety. The survival time from initiation of oxygen therapy in ILD was a median 8.4 months (IQR 3.4–19.2 months).

Conclusions Patients with ILD receive poorer access to specialist EOL care services and experience more breathlessness than patients with lung cancer. This study highlights the need of better EOL care in oxygen-dependent ILD.

  • Interstitial Fibrosis
  • Palliative Care
  • Long Term Oxygen Therapy (LTOT)
  • Idiopathic pulmonary fibrosis
  • Lung Cancer

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    Nicholas Hart Gisli Jenkins Alan Smyth